Get started
Author

Julia Piasecki

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
2023 · Paula Rodriguez-Otero, Sikander Ailawadhi, et al. · New England Journal of Medicine · 776
PDF
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
2014 · Jonathan D. Graves, Jennifer J. Kordich, et al. · Cancer Cell · 157
PDF
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
2018 · Sham Mailankody, Myo Htut, et al. · Blood · 114
Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade
2017 · Achim K. Moesta, Keegan Cooke, et al. · Clinical Cancer Research · 108
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
2024 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Blood · 78
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
2010 · Pamela M. Holland, Robert Miller, et al. · Cancer Biology & Therapy · 39
PDF
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
2023 · Paula Rodríguez Otero, Sikander Ailawadhi, et al. · Blood · 16
Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence
2020 · Lucrezia Colonna, Garnet Navarro, et al. · Blood · 15
Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).
2021 · Luciano J. Costa, Sham Mailankody, et al. · Journal of Clinical Oncology · 13
Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma
2025 · Fan Wu, Jian Zhou, et al. · Clinical Pharmacokinetics · 11
PDF
P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
2023 · Hermann Einsele, Paula Rodriguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025 · Hongxiang Hu, Yan Li, et al. · Clinical Cancer Research · 10
Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)
2020 · Julia Piasecki, Todd Devries, et al. · Blood · 7
Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers
2017 · S. Peterson, P. de Vries, et al. · Annals of Oncology · 6
PDF
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3
2023 · Rachid Baz, Paula Rodriguez Otero, et al. · Blood · 5
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma
2025 · Fan Wu, Xirong Zheng, et al. · The Journal of Clinical Pharmacology · 4
PDF
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
2023 · Julia Piasecki, Keyur Desai, et al. · Journal of Clinical Oncology · 4
PDF
Abstract 4287: Talimogene laherparepvec activates systemic T-cell-mediated anti-tumor immunity
2015 · Julia Piasecki, Jim Rottman, et al. · Cancer Research · 4
Abstract 258: Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade
2015 · Julia Piasecki, Tiep le, et al. · Cancer Research · 4
Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity
2013 · Julia Piasecki, Le Tiep, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
2024 · Paula Rodriguez-Otero, Sikander Ailawadhi, et al. · Future Oncology · 3
Induction of Transgene-Specific Cytotoxic T Lymphocyte Responses After Transplantation of Gene-Modified CD34 + Cells Despite Nonablative Immunosuppressive Conditioning
2007 · Julia C. Piasecki, Karen Beagles, et al. · Human Gene Therapy · 3
Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)
2025 · Ciara Louise Freeman, Sarah Larson, et al. · Blood · 2
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.
2024 · Ethan G. Thompson, Julia Piasecki, et al. · Journal of Clinical Oncology · 2
PDF
Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)
2024 · Krina K. Patel, Paula Rodríguez-Otero, et al. · Transplantation and Cellular Therapy · 2
Works count: 69
Citation count: 1,417
H-index: 11
I10-index: 12
Year
Topic
Type